Giacomo Zoppellaro

TL;DR: The use of rivaroxaban in high-risk patients with antiphospholipid syndrome was associated with an increased rate of events compared with warfarin, thus showing no benefit and excess risk.

TL;DR: 3DE may be a suitable alternative to conventional 2D echocardiography to assess the size and the function of cardiac chambers and may provide a more accurate and comprehensive assessment of RV size and function.

TL;DR: Three-dimensional echocardiographic LV volumes were larger, ejection fraction was similar, and LV stroke volume and mass were significantly smaller in comparison with the corresponding values obtained by conventional eChocardiography.

TL;DR: This is a multicentre, randomized, open-label, study that will evaluate if Rivaroxaban is non-inferior to warfarin for the prevention of thromboembolic events, major bleeding and death in high risk (triple positive) patients with antiphospholipid syndrome.

TL;DR: Antiphospholipid syndrome is a rare autoimmune disease characterized by a high tendency of developing thrombotic events leading to ischaemic heart disease and left ventricular dysfunction and other findings include chronic thromboembolic pulmonary hypertension and accelerated atherosclerosis.